Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

About this update from Personalis, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/ee29cd2e0e1653800154c38f89367000"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wuoLa3D90bkFrdMdf_dQjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ee29cd2e0e1653800154c38f89367000","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FEJwjbacabfjNrEzovs7uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/ee29cd2e0e1653800154c38f89367000","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests","length":112,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology","length":107,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong cash position of approximately $240 million provides capital for commercial expansion","length":92,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":432,"olType":false},{"type":"text","content":"FREMONT, Calif., February 26, 2026--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial guidance for the full year 2026.","length":336,"tagName":"p"},{"type":"text","content":"Fourth Quarter and Recent Strategic and Operational Highlights","length":62,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Secured Milestone Medicare Coverages for Breast & Lung Cancer: Received Medicare coverage approval in the fourth quarter for the surveillance of cancer recurrence in breast cancer patients, and also, received Medicare coverage for Stage I to III...

More updates from Personalis, Inc.